High-risk Myelodysplastic Syndromes With Excess Blasts
1 clinical trials · Condition
◉ Watch High-risk Myelodysplastic Syndromes With Excess Blasts
| Record | Firm | Date |
|---|---|---|
| High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE) (NCT03217903) | Central Hospital, Nancy, France | 2017-10-12 |
Track High-risk Myelodysplastic Syndromes With Excess Blasts automatically
Every clearance here is in the API, with alerts when new ones post.